PL1735349T3 - Sposób oceny ryzyka niedokrwiennego schorzenia układu sercowo-naczyniowego za pomocą koniugatów fosforylocholiny - Google Patents
Sposób oceny ryzyka niedokrwiennego schorzenia układu sercowo-naczyniowego za pomocą koniugatów fosforylocholinyInfo
- Publication number
- PL1735349T3 PL1735349T3 PL05735991T PL05735991T PL1735349T3 PL 1735349 T3 PL1735349 T3 PL 1735349T3 PL 05735991 T PL05735991 T PL 05735991T PL 05735991 T PL05735991 T PL 05735991T PL 1735349 T3 PL1735349 T3 PL 1735349T3
- Authority
- PL
- Poland
- Prior art keywords
- assessing
- risk
- cardiovascular disease
- ischemic cardiovascular
- phosphorylcholine conjugates
- Prior art date
Links
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 title abstract 2
- 229950004354 phosphorylcholine Drugs 0.000 title abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 title 1
- 230000000302 ischemic effect Effects 0.000 title 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 230000003143 atherosclerotic effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/323—Arteriosclerosis, Stenosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52138404P | 2004-04-15 | 2004-04-15 | |
| EP05735991A EP1735349B1 (en) | 2004-04-15 | 2005-04-15 | Method of assessing the risk of ischemic cardiovascular disease using phosphorylcholine conjugates |
| PCT/GB2005/001463 WO2005100405A2 (en) | 2004-04-15 | 2005-04-15 | Phosphorylcholine conjugates and corresponding antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1735349T3 true PL1735349T3 (pl) | 2011-03-31 |
Family
ID=34981497
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL06077208T PL1797893T3 (pl) | 2004-04-15 | 2005-04-15 | Przeciwciała przeciwko koniugatom fosforylocholiny |
| PL05735991T PL1735349T3 (pl) | 2004-04-15 | 2005-04-15 | Sposób oceny ryzyka niedokrwiennego schorzenia układu sercowo-naczyniowego za pomocą koniugatów fosforylocholiny |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL06077208T PL1797893T3 (pl) | 2004-04-15 | 2005-04-15 | Przeciwciała przeciwko koniugatom fosforylocholiny |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US8012483B2 (pl) |
| EP (3) | EP2258728A1 (pl) |
| JP (2) | JP4891228B2 (pl) |
| CN (4) | CN105699669A (pl) |
| AT (2) | ATE480778T1 (pl) |
| AU (2) | AU2005233361B2 (pl) |
| CA (2) | CA2562550C (pl) |
| CY (2) | CY1110188T1 (pl) |
| DE (2) | DE602005023428D1 (pl) |
| DK (2) | DK1735349T3 (pl) |
| ES (2) | ES2362222T3 (pl) |
| PL (2) | PL1797893T3 (pl) |
| PT (2) | PT1735349E (pl) |
| SI (2) | SI1735349T1 (pl) |
| WO (1) | WO2005100405A2 (pl) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1827111A4 (en) | 2004-12-22 | 2015-07-22 | Avon Prod Inc | METHOD AND COMPOSITION FOR REDUCING THE APPEARANCE OF WRINKLES |
| NZ561218A (en) * | 2005-02-07 | 2011-04-29 | Univ California | Methods for reducing the symptoms of autoimmunity and inflammation using binding proteins against antigens exposed on dead or dying cells |
| US7745146B2 (en) * | 2006-07-26 | 2010-06-29 | Inova Diagnostics, Inc. | Compositions and methods for diagnosing patients with acute atherosclerotic syndrome |
| MX2009006744A (es) * | 2006-12-22 | 2009-06-30 | Abbott Lab | Panel de padecimiento cardiovascular autoinmune y metodos de utilizacion del mismo. |
| AU2008320650A1 (en) * | 2007-10-30 | 2009-05-07 | Athera Biotechnologies Ab | Diagnostic and therapeutic methods and compositions for cardiovascular disease |
| CN102124342A (zh) | 2008-07-07 | 2011-07-13 | 阿瑟拉生物技术公司 | 阿尔茨海默病新的治疗和诊断方法 |
| CU23736A1 (es) | 2009-05-04 | 2011-11-15 | Centro Inmunologia Molecular | Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso |
| EP2542580B1 (en) * | 2010-03-04 | 2021-08-04 | Athera Biotechnologies AB | Antibodies against phosphorylcholine in combination therapy with biologic agents |
| WO2012010291A1 (en) | 2010-07-21 | 2012-01-26 | Athera Biotechnologies Ab | Diagnostic and therapeutic methods and compositions for metabolic disease |
| JP5904553B2 (ja) * | 2010-11-17 | 2016-04-13 | 国立大学法人愛媛大学 | 自己免疫疾患に関与するタンパク質の解析方法及び該疾患の検査方法 |
| EP2741770A4 (en) * | 2011-08-09 | 2014-12-31 | Athera Biotechnologies Ab | ANTIBODY BINDING TO PHOSPHORYLCHOLIN (PC) AND / OR PC CONJUGATES |
| EP2742068B1 (en) * | 2011-08-09 | 2019-04-03 | Athera Biotechnologies AB | New antibodies against phosphorylcholine |
| EP2953978B1 (en) | 2013-02-05 | 2024-10-23 | Tpcera Ltd. | Phosphorylcholine conjugates and uses thereof |
| US10046021B2 (en) | 2013-02-05 | 2018-08-14 | Tpcera Ltd. | Phosphorylcholine conjugates and uses thereof |
| US10500260B2 (en) * | 2014-02-04 | 2019-12-10 | 3Dt Holdings, Llc | Substances, vaccines and methods for diagnosing and reducing incidences of transplant rejection |
| US11065319B2 (en) * | 2014-02-04 | 2021-07-20 | 3Dt Holdings, Llc | Methods for diagnosing and reducing incidences of cardiac allograft rejection |
| JP6547755B2 (ja) | 2014-10-15 | 2019-07-24 | 日油株式会社 | ホスホリルコリン基含有化合物およびホスホリルコリン複合体 |
| CN105175504A (zh) * | 2015-09-08 | 2015-12-23 | 苏州普罗达生物科技有限公司 | 血管性血友病因子抑制多肽及其应用 |
| WO2018220224A1 (en) * | 2017-06-02 | 2018-12-06 | Medirista Biotechnologies Ab | Lipid-related antigens and antibodies directed against them |
| AU2021251423A1 (en) * | 2020-04-10 | 2022-10-27 | Vanudis GmbH | Natural antibodies in prophylaxis and therapy |
| GB2622559A (en) * | 2022-05-10 | 2024-03-27 | Johan Frostegaard | Compositions, methods and uses |
| WO2024028192A1 (de) | 2022-08-04 | 2024-02-08 | Pentracor Gmbh | Verwendung von phosphocholin-humanserumalbumin-konjugaten zur blockade von c-reaktivem protein |
| AU2024240129A1 (en) | 2023-03-17 | 2025-10-09 | Oxitope Pharma B.V. | Anti-phosphocholine antibodies and methods of use thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2402664A1 (fr) | 1977-09-07 | 1979-04-06 | Agronomique Inst Nat Rech | Produits de couplage phosphorylcholine, composes amines procede d'obtention et applications |
| JPS6251699A (ja) * | 1985-08-30 | 1987-03-06 | Nichirei:Kk | 単クロ−ン性抗体およびそれを用いる測定法 |
| US5955584A (en) * | 1986-03-31 | 1999-09-21 | Charter Ventures | Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof |
| ES2070820T3 (es) | 1986-08-06 | 1995-06-16 | Scripps Clinic Res | Anticuerpos monoclonales especificos de la apolipoproteina b, producidos por dos nuevos hibridomas. |
| JPH02188532A (ja) | 1989-01-17 | 1990-07-24 | Otsuka Pharmaceut Co Ltd | リポソームワクチン |
| WO1990012632A1 (en) * | 1989-04-19 | 1990-11-01 | The United States Of America, Represented By The Secretary, United States Department Of Commerce | Process for removing c-reactive protein and anti-phosphorylcholine antibodies from biological fluids |
| JP3283041B2 (ja) * | 1990-07-13 | 2002-05-20 | 学校法人藤田学園 | 人工抗体 |
| EP0562020A4 (en) | 1990-12-10 | 1993-11-18 | Alving, Carl L. | A vaccine against cholesterol to prevent hypercholesterolemia and atherosclerosis |
| EP0631624A1 (en) * | 1992-03-03 | 1995-01-04 | The Rockefeller University | Receptor complexes with b29 (ig-beta or ig-gamma) and their uses |
| WO1994014454A1 (en) * | 1992-12-29 | 1994-07-07 | Entremed, Inc. | Vaccines against sterols |
| MX9401351A (es) | 1993-02-22 | 1994-08-31 | Alza Corp | Composiciones para suministro oral para agentes activos. |
| US5455032A (en) | 1993-07-29 | 1995-10-03 | The United States Of America As Represented By The Department Of Health And Human Services | Use of phosphocholine hapten conjugates in vaccines |
| US6375925B1 (en) | 1996-11-08 | 2002-04-23 | The Regents Of The University Of California | Methods and reagents for non-invasive imaging of atherosclerotic plaque |
| AU1159497A (en) | 1996-11-08 | 1998-06-03 | Regents Of The University Of California, The | Methods and reagents for non-invasive imaging of atherosclerotic plaque |
| US6225070B1 (en) | 1997-08-07 | 2001-05-01 | The Regents Of The University Of California | Antibodies to oxidation-specific epitopes on lipoprotein and methods for their use in detecting, monitoring and inhibiting the growth of atheroma |
| US20040185039A1 (en) * | 2002-08-30 | 2004-09-23 | Heinz Kohler | Therapeutic applications of noncovalent dimerizing antibodies |
| US6300308B1 (en) * | 1997-12-31 | 2001-10-09 | Board Of Regents, The University Of Texas System | Methods and compositions for inducing autoimmunity in the treatment of cancers |
| SE9802402D0 (sv) | 1998-07-03 | 1998-07-03 | Karolinska Innovations Ab | Method of diagnosing cardiovascular disease and early atherosclerosis |
| WO2000002046A1 (en) | 1998-07-03 | 2000-01-13 | Karolinska Innovations Ab | Method of diagnosing cardiovascular disease and early atherosclerosis |
| MXPA02004244A (es) * | 1999-10-26 | 2002-11-04 | Univ California | Reactivos y metodos para el diagnostico, la formacion de imagenes y el tratamiento del padecimiento de la ateroesclerosis.. |
| SE0000855D0 (sv) | 2000-03-15 | 2000-03-15 | Karolinska Innovations Ab | Antigenic composition useful as a vaccine against atherosclerosis |
| WO2001088547A2 (en) | 2000-05-12 | 2001-11-22 | The Regents Of The University Of California | Standardized oxidized ldl assay |
| US6664230B1 (en) * | 2000-08-24 | 2003-12-16 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
| DE10041515A1 (de) * | 2000-08-24 | 2002-03-14 | Gerold Schuler | Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen |
| US6838452B2 (en) | 2000-11-24 | 2005-01-04 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
| SE0103754L (sv) * | 2001-04-05 | 2002-10-06 | Forskarpatent I Syd Ab | Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid |
| US6930085B2 (en) * | 2002-04-05 | 2005-08-16 | The Regents Of The University Of California | G-type peptides to ameliorate atherosclerosis |
| WO2004091520A2 (en) | 2003-04-11 | 2004-10-28 | The Regents Of The University Of California | Methods and compositions for treating atherosclerosis |
-
2005
- 2005-04-15 PL PL06077208T patent/PL1797893T3/pl unknown
- 2005-04-15 AU AU2005233361A patent/AU2005233361B2/en not_active Ceased
- 2005-04-15 US US10/599,934 patent/US8012483B2/en not_active Expired - Fee Related
- 2005-04-15 CA CA2562550A patent/CA2562550C/en not_active Expired - Fee Related
- 2005-04-15 ES ES05735991T patent/ES2362222T3/es not_active Expired - Lifetime
- 2005-04-15 PT PT05735991T patent/PT1735349E/pt unknown
- 2005-04-15 WO PCT/GB2005/001463 patent/WO2005100405A2/en not_active Ceased
- 2005-04-15 CN CN201610065003.2A patent/CN105699669A/zh active Pending
- 2005-04-15 CN CN200580019701.9A patent/CN1968965B/zh not_active Expired - Fee Related
- 2005-04-15 JP JP2007507849A patent/JP4891228B2/ja not_active Expired - Fee Related
- 2005-04-15 CA CA2776927A patent/CA2776927C/en not_active Expired - Fee Related
- 2005-04-15 CN CN201310484529.0A patent/CN103743898B/zh not_active Expired - Fee Related
- 2005-04-15 EP EP10007969A patent/EP2258728A1/en not_active Withdrawn
- 2005-04-15 AT AT05735991T patent/ATE480778T1/de active
- 2005-04-15 SI SI200531162T patent/SI1735349T1/sl unknown
- 2005-04-15 CN CN201410123605.XA patent/CN103908669B/zh not_active Expired - Fee Related
- 2005-04-15 DE DE602005023428T patent/DE602005023428D1/de not_active Expired - Lifetime
- 2005-04-15 DK DK05735991.1T patent/DK1735349T3/da active
- 2005-04-15 DK DK06077208.4T patent/DK1797893T3/da active
- 2005-04-15 EP EP06077208A patent/EP1797893B1/en not_active Expired - Lifetime
- 2005-04-15 DE DE602005020474T patent/DE602005020474D1/de not_active Expired - Lifetime
- 2005-04-15 PT PT06077208T patent/PT1797893E/pt unknown
- 2005-04-15 AT AT06077208T patent/ATE463254T1/de active
- 2005-04-15 ES ES06077208T patent/ES2357606T3/es not_active Expired - Lifetime
- 2005-04-15 PL PL05735991T patent/PL1735349T3/pl unknown
- 2005-04-15 EP EP05735991A patent/EP1735349B1/en not_active Expired - Lifetime
- 2005-04-15 SI SI200531048T patent/SI1797893T1/sl unknown
-
2010
- 2010-07-07 CY CY20101100630T patent/CY1110188T1/el unknown
- 2010-12-06 CY CY20101101123T patent/CY1111659T1/el unknown
-
2011
- 2011-02-07 JP JP2011024073A patent/JP5366987B2/ja not_active Expired - Fee Related
- 2011-05-19 AU AU2011202334A patent/AU2011202334B2/en not_active Ceased
- 2011-08-11 US US13/208,138 patent/US20120039895A1/en not_active Abandoned
-
2014
- 2014-01-15 US US14/155,903 patent/US10222382B2/en not_active Expired - Fee Related
-
2015
- 2015-11-06 US US14/935,044 patent/US20160131661A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL1735349T3 (pl) | Sposób oceny ryzyka niedokrwiennego schorzenia układu sercowo-naczyniowego za pomocą koniugatów fosforylocholiny | |
| CY2024006I1 (el) | Διαμινοπυριμιδινες ως ρ2χ3 και ρ2χ2/3 ανταγωνιστες | |
| NO20054451D0 (no) | Fremgangsmate og innretning for friksjonssveising | |
| WO2007044026A3 (en) | Compositions comprising modified collagen and uses therefore | |
| NL1026089A1 (nl) | Scintillator welke een geïntegreerde collimator heeft en werkwijze voor het vervaardigen daarvan. | |
| ATE399802T1 (de) | Amidfunktionelle polymere, zusammensetzungen und verfahren | |
| WO2008060618A3 (en) | Use of genetic determinants in cardiovascular risk assessment | |
| DE602006019404D1 (de) | Docetaxel-immuntest | |
| ITMI20061751A1 (it) | Albero cavo e procedimento per la realizzazione | |
| ATE549416T1 (de) | Verfahren und zusammensetzungen zum nachweis von autoimmunkrankheiten | |
| NL1024195A1 (nl) | Inspectiewerkwijze voor een belichtingsinrichting en een belichtingsinrichting. | |
| WO2006138048A3 (en) | Formulations comprising fluphenazine or derivatives thereof | |
| BRPI0402499B1 (pt) | armação lateral e método para reparar ou manter uma armação lateral para um conjunto roda-truque de vagão ferroviário que suporta um vagão ferroviário. | |
| NL1021785A1 (nl) | Inrichting en werkwijze voor het belichten van een object. | |
| IL185653A0 (en) | Pharmaceutical compositions containing an antibody which binds the stalk region of kim-1 | |
| MX2007009591A (es) | Metodos para disposicion mejorada de farmacos. | |
| EP1427429A4 (en) | COMPOSITIONS AND METHODS OF TREATING PATIENTS WITH HYPERGLYCEMIA | |
| NL1028882A1 (nl) | Werkwijze voor de inspectie van metalen ringen en inrichting voor de inspectie van metalen ringen. | |
| WO2006074443A3 (en) | Pde5 inhibitor compositions and methods for immunotherapy | |
| DE602006004017D1 (de) | Ausrichtungsvorrichtung und -verfahren | |
| FR2893871B1 (fr) | Procede et dispositif d'allumage d'une composition aluminothermique et creuset de soudure aluminothermique comportant le dispositif. | |
| FR2893833B1 (fr) | Appareil d'orthopedie dento-faciale. | |
| DE60317303D1 (de) | Hemoglobin Konjugate | |
| ITUD20040001A1 (it) | Procedimento per la rilevazione in linea | |
| ES1058260Y (es) | Dispositivo para arreglos florales, en especial para coronas funebres. |